Naoto Takahashi

Prof. Naoto Takahashi

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IMIchiro Morioka
Ichiro Morioka
YKYasumasa Kakei
Yasumasa Kakei
TOTakashi Omori
Takashi Omori
KNKandai Nozu
Kandai Nozu
Kazumichi FujiokaKazumichi Fujioka
Kazumichi Fujioka
AOAkira Oka
Akira Oka
Our aims were to determine the clinical impact of oral valganciclovir (VGCV) in infants aged ≤2 months with congenital cytomegalovirus (CMV) disease and evaluate the efficacy of VGCV when initiated beyond the neonatal period. The multicenter, single-arm, open-label clinical trial was conducted in Japan. Twenty-five infants aged ≤2 months with congenital CMV disease involving the central nervous system were enrolled and treated with VGCV for 6 months. The primary endpoint was the change in the whole blood CMV load before and after treatment. The secondary endpoint was the change in the auditory brainstem response (ABR) before and after treatment. Changes in ABR were assessed between the younger and older age groups (≤ and >30 days at treatment initiation). Of the 25 patients, one was excluded owing to epilepsy before VGCV administration. The median change in the CMV DNA level in whole blood was −246.0 IU/mL. The best ear and total ear assessments based on ABR were categorized as (improved + unchanged) after treatment for 100% and 93.8%, respectively. No differences in hearing efficacy were observed between the younger and older age groups. Oral VGCV is a potential therapeutic option for treating infants aged ≤2 months with congenital CMV disease.

1 January 2023 in Pediatrics International
Verified
Journal Article
Closed access
TMTokuo Miyazawa
Tokuo Miyazawa
HAHitomi Arahori
Hitomi Arahori
SOSatoshi Ohnishi
Satoshi Ohnishi
HSHromichi Shoji
Hromichi Shoji
AMAtsushi Matsumoto
Atsushi Matsumoto
Katsumi MizunoKatsumi Mizuno
Katsumi Mizuno

21 May 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
HSHiromichi Shoji
Hiromichi Shoji
HAHiroko Arai
Hiroko Arai
SKSatsuki Kakiuchi
Satsuki Kakiuchi
AIAtsushi Ito
Atsushi Ito
KSKeigo Sato
Keigo Sato
TSToshiaki Shimizu
Toshiaki Shimizu
The binding ratio of palmitic acid (PA) at the sn-2 position of triacylglycerols in infant formulas is lower than that in breast milk, resulting in higher levels of fecal PA. Even if the ratio is increased to 40–50%, fecal PA levels in formula-fed infants remain higher than those in breast–fed infants. In Japan, infant formulas with 50% or more of PA bound to sn-2 (high sn-2 PA milk) are commercially available; however, their effects on PA excretion have not been investigated. Therefore, this observational study aimed to preliminarily evaluate whether the feeding volume of high sn-2 PA milk is significantly associated with fecal total/soaped PA levels in newborns. Infant formulas were classified as high (≥50% of PA bound to sn-2) or low sn-2 (<50%) PA milk. Associations between feeding volume of high or low sn-2 PA milk and fecal PA levels were evaluated using multiple regression analysis models. The results showed that the feeding volume of low sn-2 PA milk was positively associated with fecal total/soaped PA levels, while there was no significant association between those of high sn-2 PA milk and fecal total/soaped PA levels. Our preliminary study suggests that high sn-2 PA milk may reduce increased fecal PA levels in formula-fed newborns.

26 September 2024 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
KYKota Yoneda
Kota Yoneda
DSDaisuke Shinjo
Daisuke Shinjo
NTNaoto Takahashi
Naoto Takahashi
KFKiyohide Fushimi
Kiyohide Fushimi
Background: Kawasaki disease (KD) is an acute vasculitis primarily affecting children. While some studies suggest a link between KD and PM2.5exposure, findings remain inconsistent. This study aimed to perform spatiotemporal analysis to investigate the impact of monthly and annual exposure to PM2.5and other air pollutants on the incidence of KD before and after the advent of the COVID-19 pandemic.Methods: In this retrospective analysis, we used the Japanese administrative claims database to identify the incidence of KD in children under age 5 in 335 secondary medical care areas across Japan before (from July 2014 to December 2019) and during (from January 2020 to December 2021) the COVID-19 pandemic. For each of these periods, we developed hierarchical Bayesian models termed conditional autoregressive (CAR) models that can address the spatiotemporal clustering of KD to investigate the association between the monthly incidence of KD and exposure to PM2.5, NO, NO2and SO2over 1-month and 12-month durations. The pollution data were collected from publicly available data provided by the National Institute for Environmental Studies.Results: In the before-pandemic and during-pandemic periods, 55 289 and 14 023 new cases of KD were identified, respectively. The CAR models revealed that only 12-month exposure to PM2.5was consistently correlated with KD incidence, and each 1 µg/m3increase in annual PM2.5exposure corresponded to a 3%–10% rise in KD incidence. Consistent outcomes were observed in the age-stratified sensitivity analysis.Conclusions: Annual exposure to PM2.5was robustly linked with the onset of KD. Further research is needed to elucidate the underlying mechanism by which the spatiotemporal distribution of PM2.5is associated with KD.


13 March 2024 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YKYasumasa Kakei
Yasumasa Kakei
IMIchiro Morioka
Ichiro Morioka
TITakumi Imai
Takumi Imai
KIKotaro Itohara
Kotaro Itohara
IYIkuko Yano
Ikuko Yano
TMTeranishi Masaaki
Teranishi Masaaki